Back to results
US 11,999,790 B2Granted
Anti-OX40 antibodies and uses thereof
AssigneeEucure (Beijing) Biopharma Co., Ltd
InventorsYi Yang, Yanan Guo, Yunyun Chen, Jingshu Xie, Chunyan Dong, Fang Yang, Chengyuan Lu, Xiaodong Cheng, Yuelei Shen, Jian Ni
Life of this patent
Estimating the term…
Abstract
This disclosure relates to anti-human OX40 (TNF Receptor Superfamily Member 4, or TNFRSF4) antibodies, antigen-binding fragments, and the uses thereof.
Claims17
An antibody or antigen-binding fragment thereof that binds to human OX40 (TNF Receptor Superfamily Member 4) comprising:
- a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is identical to a selected VH CDR3 amino acid sequence;
- and
- a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is identical to a selected VL CDR3 amino acid sequence,
- wherein the selected VH CDRs 1, 2, and 3 amino acid sequences and the selected VL CDRs, 1, 2, and 3 amino acid sequences are one of the following:
- (1) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 1, 2, 3, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 4, 5, 6, respectively;
- (2) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 25, 26, 27, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 28, 29, 30, respectively;
- (3) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 7, 8, 9, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 10, 11, 12, respectively;
- (4) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 31, 32, 33, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 34, 35, 36, respectively;
- (5) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 13, 14, 15, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 16, 17, 18, respectively;
- (6) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 37, 38, 39, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 40, 41, 42, respectively;
- (7) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 19, 20, 21, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 22, 23, 24, respectively;
- and
- (8) the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 43, 44, 45, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 46, 47, 48, respectively.
26 more elements
A nucleic acid comprising a polynucleotide encoding a polypeptide comprising:
- (1) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 1, 2, and 3, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:
- 56, 57, 58, or 80, binds to human OX40;
- (2) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 4, 5, and 6, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:
- 53, 54, 55, or 79, binds to human OX40;
- (3) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 7, 8, and 9, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO:
- 62, 63, 64, 65, or 82, binds to human OX40;
- or
- (4) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 10, 11, and 12, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:
- 59, 60, 61, or 81, binds to human OX40;
- (5) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 13, 14, and 15, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs:
- 69, 70, 71, 72, or 84 binds to human OX40;
- (6) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 16, 17, and 18, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NOs:
- 66, 67, 68, or 83, binds to human OX40;
- (7) an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH) comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 19, 20, and 21, respectively, and wherein the VH, when paired with a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NOs:
- 76, 77, 78, or 86, binds to human OX40;
- or
- (8) an immunoglobulin light chain or a fragment thereof comprising a VL comprising CDRs 1, 2, and 3 comprising the amino acid sequences set forth in SEQ ID NOs:
- 22, 23, and 24, respectively, and wherein the VL, when paired with a VH comprising the amino acid sequence set forth in SEQ ID NO:
- 73, 74, 75, or 85, binds to human OX40.
23 more elements
An antibody or antigen-binding fragment thereof that binds to human OX40, comprising a heavy chain variable region comprising VH CDRs 1, 2, 3, and a light chain variable region comprising VL CDRs 1, 2, 3, wherein:
- (1) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO:
- 53, 54, 55, or 79, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO:
- 56, 57, 58, or 80;
- (2) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO:
- 59, 60, 61, or 81, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO:
- 62, 63, 64, 65, or 82;
- (3) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO:
- 66, 67, 68, or 83, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO:
- 69, 70, 71, 72, or 84;
- or
- (4) the VH CDRs 1, 2, 3 are identical to complementarity determining regions in SEQ ID NO:
- 73, 74, 75, or 85, and the VL CDRs 1, 2, 3 are identical to complementary determining regions in SEQ ID NO:
- 76, 77, 78, or 86.
10 more elements
Dependencies are inferred from the claim text.